Graphene + DNA = The Quantum Brain Singularity: PROCESS

 

 A new collaborative post by my mate and buddy Captain Wardrobe... and research by me too.. A work in progress.

Enjoy! A13

THE HIVE ? HEX? or Fence ? or all of them?

Delta Variant new wave rinse & repeat
The PCR / Vaccine merry go round?
Graphene...and the coming
Robotnik quantum brain

 

Capt Wardrobe / Thirteenth Monkey - July 2021

 

July 2021 - what a surprise!
Delta Variant panic globally

Pictures tell stories

Update on the global situation

THE PCR VACCINE MERRY GO ROUND? Swab humanitys DNA Use PCR to make RNA into cDna (legally patentable) as a copy Dna database scan using AI to find variants Use CT PCR to extract cRna from variant sample Place cRna variant sample in Mrna gene therapy (now labelled as vaccine)

Covid 19 / Sars Cov 2 PCR tests rely on swabbed samples

now please take a look at this Epstein bribery network / transhumanism / human genepool / life extension / autism / Talpiot / supersoldiers / clones / spying on kids / AI sophia / AI Dolls for kids 2004 - An mRNA amplification procedure with directional cDNA cloning and strand-specific cRNA synthesis for comprehensive gene expression analysis A mechanism for prime-realignment during influenza A virus replication The R251K Substitution in Viral Protein PB2 Increases Viral Replication and Pathogenicity of Eurasian Avian-like H1N1 Swine Influenza Viruses

"PCR can generate 100 billion similar molecules in an afternoon." Kary B. Mullis: The Unusual Origin of the Polymerase Chain Reaction (Scientific American April 1990) GENERATE it allows for the unlimited replication of small bits of DNa HOW DIFFERENT TO THIS IS CLONING? what has PCR testing done? replicated a, upon all evidence available, a reletavily harmless, Novel coronavirus disease, "amplified" it to what?...think about the possibilities of that... where is the DNA material disposed?

what happens to the replicated DNA material from everyone that's tested? Are Humans being swabbed on mass for DNA for a reason? is there a specific DNA being looked for? For Military bioweapons R&D? PCR inventor Kary Mullis is credited with making the human genome project possible I fear a genetic library of humanity is being assembled and from that library any one can be cloned. humanity produced like off the shelf consumerables From Down with Murder inc - The New Slavery 2002

"...is the drive for COVID-19 testing just a smokescreen with regard to the PCR test? The answer to this simple question is a straightforward yes, it is. In reality, the PCR tests have another much more important role, and that is sampling DNA data to facilitate genome sequencing, the name for reading the genetic code for the makeup of the human body." click on pic for article/ video

MRHA - The original DnA template for Sars Cov 2
did NOT come from an
isolated virus or an infected person

PCR swabbing & testing

 

 

What's really going on?

With regard to RT-PCR assays, given that all coronaviruses have an RNA genome, it is necessary to synthesize complementary DNA (cDNA) from the RNA genome through reverse transcription, followed by PCR amplification of the cDNA with specific primers for the SARS-CoV-2 genes of interest. While all NAATs that utilize RT-PCR detect SARS-CoV-2 in this way, there are many variations that can be applied for the actual detection of the amplified genes. Most common is the use of a real-time RT-PCR, which employs fluorescence to detect the amount of amplified DNA in real time. A frequently utilized example of this is TaqMan hydrolysis. [38] In real-time RT-PCR, the amount of gene target present in the sample typically determines the number of PCR cycles (known as the cycle threshold [Ct] value) needed before SARS-CoV-2 is detected. Medscape

cDNA WAS RULED PATENTABLE see page 3 and Nature article here GUESS WHAT PCR TESTS GENERATE FROM human swabbed source RNA? cDNA classed as not 'human' & Patentable. this is precisely why PcR should not be used in diagnostic situations so a human dna database collected from swabed PCR tests would contain patented cDNA generated from from the human population sound a bit dodgy? yup not as dodgy as generating new variants from the cDna collected and making a Mrna gene therapy into a politically useful bioweapon

Reverse transcriptases (RTs) are RNA-directed DNA polymerases that were first identified as part of the retroviral life cycle (Temin and Mizutani, 1970, Baltimore, 1970). RTs catalyze the synthesis of a DNA copy (cDNA) of the target RNA molecules using a reverse transcription primer, dNTPs, and Mg2+ or Mn2+ as a cofactor. Reverse transcriptases have been adapted for use in a variety of in vitro applications including real-time and endpoint RT-PCR, labeled-cDNA probe generation and cDNA library construction. promega.com

Via The New York Times Vaccine tracker

The initial Vaccine trials were useless

Will covid-19 vaccines save lives? Current trials aren’t designed to tell us BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4037 (Published 21 October 2020) Cite this as: British medical Journal - BMJ 2020;371:m4037 Linked Editorial - Peter Doshi, associate editor - pdoshi@bmj.com Covid-19 vaccine trial protocols released The world has bet the farm on vaccines as the solution to the pandemic, but the trials are not focused on answering the questions many might assume they are. Peter Doshi reports As phase III trials of covid-19 vaccines reach their target enrolments, officials have been trying to project calm. The US coronavirus czar Anthony Fauci and the Food and Drug Administration leadership have offered public assurances that established procedures will be followed.1234 Only a "safe and effective" vaccine will be approved, they say, and nine vaccine manufacturers issued a rare joint statement pledging not to prematurely seek regulatory review.5 But what will it mean exactly when a vaccine is declared "effective"? To the public this seems fairly obvious. "The primary goal of a covid-19 vaccine is to keep people from getting very sick and dying," a National Public Radio broadcast said bluntly.6 Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, said, "Ideally, you want an antiviral vaccine to do two things . . . first, reduce the likelihood you will get severely ill and go to the hospital, and two, prevent infection and therefore interrupt disease transmission."7 Yet the current phase III trials are not actually set up to prove either (table 1). None of the trials currently under way are designed to detect a reduction in any serious outcome such as hospital admissions, use of intensive care, or deaths. Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus. Table 1 Characteristics of ongoing phase III covid-19 vaccine trials Evaluating mild, not severe, disease In a September interview Medscape editor in chief Eric Topol pondered what counts as a recorded "event" in the vaccine trials. "We’re not talking about just a PCR [polymerase chain reaction test]-positive mild infection. It has to be moderate to severe illness to qualify as an event, correct?" he asked.8 "That’s right," concurred his guest, Paul Offit, a vaccinologist who sits on the FDA advisory committee that may ultimately recommend the vaccines for licence or emergency use authorisation. But that’s not right. In all the ongoing phase III trials for which details have been released, laboratory confirmed infections even with only mild symptoms qualify as meeting the primary endpoint definition.9101112 In Pfizer and Moderna’s trials, for example, people with only a cough and positive laboratory test would bring those trials one event closer to their completion. (If AstraZeneca’s ongoing UK trial is designed similarly to its "paused" US trial for which the company has released details, a cough and fever with positive PCR test would suffice.) Part of the reason may be numbers. Severe illness requiring hospital admission, which happens in only a small fraction of symptomatic covid-19 cases, would be unlikely to occur in significant numbers in trials. Data published by the US Centers for Disease Control and Prevention in late April reported a symptomatic case hospitalisation ratio of 3.4% overall, varying from 1.7% in 0-49 year olds and 4.5% in 50-64 year olds to 7.4% in those 65 and over.13 Because most people with symptomatic covid-19 experience only mild symptoms,14 even trials involving 30?000 or more patients would turn up relatively few cases of severe disease. In the trials, final efficacy analyses are planned after just 150 to 160 "events,"—that is, a positive indication of symptomatic covid-19, regardless of severity of the illness. Yet until vaccine manufacturers began to release their study protocols in mid-September, trial registries and other publicly released information did little to dispel the notion that it was severe covid-19 that the trials were assessing. Moderna, for example, called hospital admissions a "key secondary endpoint" in statements to the media.15 And a press release from the US National Institutes of Health reinforced this impression, stating that Moderna’s trial "aims to study whether the vaccine can prevent severe covid-19" and "seeks to answer if the vaccine can prevent death caused by covid-19."16 But Tal Zaks, chief medical officer at Moderna, told The BMJ that the company’s trial lacks adequate statistical power to assess those outcomes. "The trial is precluded from judging [hospital admissions], based on what is a reasonable size and duration to serve the public good here," he said. Hospital admissions and deaths from covid-19 are simply too uncommon in the population being studied for an effective vaccine to demonstrate statistically significant differences in a trial of 30?000 people. The same is true of its ability to save lives or prevent transmission: the trials are not designed to find out. Zaks said, "Would I like to know that this prevents mortality? Sure, because I believe it does. I just don’t think it’s feasible within the timeframe [of the trial]—too many would die waiting for the results before we ever knew that." Stopping transmission What about Hotez’s second criterion, interrupting virus transmission, which some experts have argued17 should be the most important test in phase III studies? "Our trial will not demonstrate prevention of transmission," Zaks said, "because in order to do that you have to swab people twice a week for very long periods, and that becomes operationally untenable." He repeatedly emphasised these "operational realities" of running a vaccine trial. "Every trial design, especially phase III, is always a balancing act between different needs," he said. "If you wanted to have an answer on an endpoint that happens at a frequency of one 10th or one fifth the frequency of the primary endpoint, you would need a trial that is either 5 or 10 times larger or you’d need a trial that is 5 or 10 times longer to collect those events. Neither of these, I think, are acceptable in the current public need for knowing expeditiously that a vaccine works." Zaks added, "A 30?000 [participant] trial is already a fairly large trial. If you’re asking for a 300 000 trial then you need to talk to the people who are paying for it, because now you’re talking about not a $500m to $1bn trial, you’re talking about something 10 times the size. And I think the public purse and operational capabilities and capacities we have are rightly spent not betting the farm on one vaccine but, as Operation Warp Speed [the US government’s covid-19 vaccine plan] is trying to do, making sure that we’re funding several vaccines in parallel." Debating endpoints Still, it’s fair to say that most of the general public assumes that the whole point of the current trials, besides testing safety (box 1), is to see whether the vaccine can prevent bad outcomes. "How do you reconcile that?" The BMJ asked Zaks. Box 1 Safety and side effects History shows many examples of serious adverse events from vaccines brought to market in periods of enormous pressure and expectation. There were contaminated polio vaccines in 1955, cases of Guillain-Barré syndrome in recipients of flu vaccines in 1976, and narcolepsy linked to one brand of influenza vaccine in 2009.1819 "Finding severe rare adverse events will require the study of tens of thousands of patients, but this requirement will not be met by early adoption of a product that has not completed its full trial evaluation," Harvard drug policy researchers Jerry Avorn and Aaron Kesselheim recently wrote in JAMA.20 Covid-19 vaccine trials are currently designed to tabulate final efficacy results once 150 to 160 trial participants develop symptomatic covid-19—and most trials have specified at least one interim analysis allowing for the trials to end with even fewer data accrued. Medscape’s Eric Topol has been a vocal critic of the trials’ many interim analyses. "These numbers seem totally out of line with what would be considered stopping rules," he says. "I mean, you’re talking about giving a vaccine with any of these programmes to tens of millions of people. And you’re going to base that on 100 events?"8 Great uncertainty remains over how long a randomised trial of a vaccine will be allowed to proceed. If efficacy is declared, one possibility is that the thousands of volunteers who received a saline placebo would be offered the active vaccine, in effect ending the period of randomised follow-up. Such a move would have far reaching implications for our understanding of vaccines’ benefits and harms, rendering uncertain our knowledge of whether the vaccines can reduce the risk of serious covid-19 disease and precluding any further ability to compare adverse events in the experimental versus the placebo arm. "It’ll be a decision we’ll have to take at that time. We have not committed one way or another," Moderna’s Tal Zaks told The BMJ. "It will be a decision where FDA and NIH will also weigh in. And it will be probably a very difficult decision, because you will be weighing the benefit to the public in continuing to understand the longer term safety by keeping people on placebo and the expectation of the people who have received placebo to be crossed over now that it has been proved effective." "Very simply," he replied. "Number one, we have a bad outcome as our endpoint. It’s covid-19 disease." Moderna, like Pfizer and Janssen, has designed its study to detect a relative risk reduction of at least 30% in participants developing laboratory confirmed covid-19, consistent with FDA and international guidance.2122 Number two, Zaks pointed to influenza vaccines, saying they protect against severe disease better than mild disease. To Moderna, it’s the same for covid-19: if its vaccine is shown to reduce symptomatic covid-19, it will be confident it also protects against serious outcomes. But the truth is that the science remains far from clear cut, even for influenza vaccines that have been used for decades. Although randomised trials have shown an effect in reducing the risk of symptomatic influenza, such trials have never been conducted in elderly people living in the community to see whether they save lives. Only two placebo controlled trials in this population have ever been conducted, and neither was designed to detect any difference in hospital admissions or deaths.23 Moreover, dramatic increases in use of influenza vaccines has not been associated with a decline in mortality (box 2).26 Box 2 Not enrolling enough elderly people or minorities A vaccine that has been proved to reduce the risk of symptomatic disease by a certain proportion should, you might think, reduce serious outcomes such as hospital admissions and deaths in equal proportion. Peter Marks, an FDA official with responsibility over vaccine approvals, recently stated as much about influenza vaccination, which "only prevents flu in about half the people who get it. And yet that’s very important because that means that it leads to half as many deaths related to influenza each year."24 But when vaccines are not equally effective in all populations the theory breaks down. If frail elderly people, who are understood to die in disproportionate numbers from both influenza25 and covid-19, are not enrolled into vaccine trials in sufficient numbers to determine whether case numbers are reduced in this group, there can be little basis for assuming any benefit in terms of hospital admissions or mortality. Whatever reduction in cases is seen in the overall study population (most of which may be among healthy adults), this benefit may not apply to the frail elderly subpopulation, and few lives may be saved. This is hard to evaluate in the current trials because there are large gaps in the types of people being enrolled in the phase III trials (table 1). Despite recruiting tens of thousands, only two trials are enrolling children less than 18 years old. All exclude immunocompromised people and pregnant or breastfeeding women, and though the trials are enrolling elderly people, few or perhaps none of the studies would seem to be designed to conclusively answer whether there is a benefit in this population, despite their obvious vulnerability to covid-19. "Adults over 65 will be an important subgroup that we will be looking at," Moderna’s Zaks told The BMJ. "That said . . . any given study is powered for its primary endpoint—in our case covid-19 disease irrespective of age." Al Sommer, dean emeritus of the Johns Hopkins School of Public Health, told The BMJ, "If they have not powered for evidence of benefit in the elderly, I would find that a significant, unfortunate shortcoming." He emphasised the need for "innovative follow-up studies that will enable us to better determine the direct level of protection immunisation has on the young and, separately, the elderly, in addition to those at the highest risk of severe disease and hospitalisation." One view is that trial data should be there for all target populations. "If we don’t have adequate data in the greater than 65 year old group, then the greater than 65 year old person shouldn’t get this vaccine, which would be a shame because they’re the ones who are most likely to die from this infection," said vaccinologist Paul Offit.8 "We have to generate those data," he said. "I can’t see how anybody—the Data and Safety Monitoring Board or the FDA Vaccine Advisory Committee, or FDA decision-makers—would ever allow a vaccine to be recommended for that group without having adequate data." "I feel the same way about minorities," Offit added. "You can’t convince minority populations to get this vaccine unless they are represented in these trials. Otherwise, they’re going to feel like they’re guinea pigs, and understandably so."

Summary The mRNA-based BNT162b2 vaccine from Pfizer/BioNTech was the first registered COVID-19 vaccine and has been shown to be up to 95% effective in preventing SARS-CoV-2 infections. Little is known about the broad effects of the new class of mRNA vaccines, especially whether they have combined effects on innate and adaptive immune responses. Here we confirmed that BNT162b2 vaccination of healthy individuals induced effective humoral and cellular immunity against several SARS-CoV-2 variants. Interestingly, however, the BNT162b2 vaccine also modulated the production of inflammatory cytokines by innate immune cells upon stimulation with both specific (SARS-CoV-2) and non-specific (viral, fungal and bacterial) stimuli. The response of innate immune cells to TLR4 and TLR7/8 ligands was lower after BNT162b2 vaccination, while fungi-induced cytokine responses were stronger. In conclusion, the mRNA BNT162b2 vaccine induces complex functional reprogramming of innate immune responses, which should be considered in the development and use of this new class of vaccines.

The Concern for the Secretive US Bio-Geopolitics Oct 10, 2019 - Dan Steinbock Founder, Difference Group excerpt - "...the neoconservative Project for New American Century (PNAC), the ideological force behind the subsequent Bush administration's foreign policy, declared in its manifesto, Rebuilding America's Defenses (2000), that 'advanced forms of biological warfare that can 'target' specific genotypes may transform biological warfare from the realm of terror to a politically useful tool." Previously, such efforts at biological 'ethnic bombs"had occurred mainly in apartheid-era South Africa and Rhodesia; the PNAC builds on the Israeli 'ethno-bomb'idea to target specific genetic traits among target populations. By May 2007, Russia banned all exports of human bio samples due to concern for "genetic bio-weapons" targeting the Russian population. Reportedly, some of these institutions, including Harvard Public Health and USAID, have collected biological material in China as well. In October 2018, Russian Defense Ministry claimed the spread of viral diseases from Georgia, including African swine fever since 2007, could be connected to a US lab network in the area, where more than 70 Georgians had died in odd conditions. The lab network, a branch of the Nunn-Lugar bio-initiative, belongs to the multimillion-dollar Cooperative Biological Engagement Program (CBEP) funded by Pentagon's Cooperative Threat Reduction Agency (DTRA). The CBEP labs are located in 25 countries, including in Eastern Europe (e.g., Georgia and Ukraine), the Middle East, Africa, and Southeast Asia. In several locations, there have been reported outbreaks of tropical diseases, which are not endemic to the area. Despite high-level Russian calls for a 'comprehensive evaluation"and 'joint inspections,"pleas for multilateral cooperation have been ignored. In its 2020 multimillion-dollar budget, the DTRA characterizes the "bio-security" program in Asia as 'the partner of choice in a region competing against Chinese influence.' China Focus     China military labs DNA database Cold war 2.0 cover story as China are once again "the bad guys" who do the 'dirty work' for the agenda... meanwhile The Bio-genomics global industry Hand in hand with the respective Military are growing exponentially:

"...advanced forms of biological warfare that can "target" specific genotypes may transform biological warfare from the realm of terror to a politically useful tool." Rebuilding Americas defenses - The Project for the New American Century - 2000

quote: "the vaccine makes the dangerous part of the virus in the body" - PETER MCCULLOUGH MD

what dangerous part? if covid is only dangerous to vulnerable people ... IE 0.02 of the population...so the question needs to be asked - what spike protiein is this mrna gene therapy producing - and is it actually a bioweapon? "As this, in a sense, bioterrorism phase one was rolled out, it was really all about keeping the population in fear and in isolation and preparing them to accept the vaccine, which appears to be phase two of a bioterrorism operation," DR, PETER MCCULLOUGH INTERVIEWED BY REINER FUELLMICH, JUNE 11, 2021 and stating that he believes the vaccine is a BIOWEAPON [video] Dr Peter McCullough MD testifies to Texas Senate HHS

wayback when - many of The US Army Spec Ops group / Rangers etc ...were chipped with Digital angel RFID chips. The program aims to develop algorithms that use raw data from smartphone sensors to enable continuous and real-time assessment of warfighters' health status, identifying latent or developing conditions and diseases" Darpa have developed real time bio data collection & analysis DARPA MhealthIntelligence smartphone collection? GAVI - Bill Gates AGAIN: who IS this woman? IMPLANTs / PILLs as ID authentication / TRACKING / BIO-MONITORING THE GLOBAL BIOSECURITY STATE IS A CORPORATE MILITARY TAKOVER

Is this real? will it be real soon?

now watch this: the following video proports to show A Hacker backdooring into Russian Sputnik MRNA database He then finds real time tracking database tracking people via whats now in their bodies after the vaccine.

Brain-accumulated graphene oxide undergoes changes consistent with biodegradation

Thin graphene oxide sheets can translocate from the nasal cavity to the brain Translocation is size dependent, with ultrasmall nanometric sheets translocating the most Kinetics of graphene oxide accumulation are time dependent and brain-region-specific Brain-accumulated graphene oxide undergoes changes consistent with biodegradation Article Nose-to-Brain Translocation and Cerebral Biodegradation of Thin Graphene Oxide NanosheetsLeon Newman,1,2 Artur Filipe Rodrigues,1,2Dhifaf A. Jasim,1,2Isabella Anna Vacchi,3Cecilia Meard-Moyon,3Alberto Bianco,3,6Cyrill Bussy,1,2,*and Kostas Kostarelos1,2,4,5,7,* SUMMARY Understanding the interactions of graphene oxide (GO)-basedmaterials with biological systems is critical due to the potentialapplications of these materials. Here, we investigate the extent towhich single- to few-layer GO sheets of different controlled lateraldimensions translocate from the nose to the brain following intra-nasal instillation. We explore tissue location andin vivobiodegrad-ability of the translocated materials using various techniques. Massspectrometry and confocal Raman analyses indicate that traceamounts of GO undergo nose-to-brain translocation in a size-depen-dent manner. The smallest GO-sheet size category (us-GO, 10-550 nm) gains the greatest access to the brain in terms of quantity science direct

La Quinta Columna made an urgent announcement that they hope will reach as many people as possible, especially those involved in health and legal services, as biostatistician Ricardo Delgado, Dr. José Luis Sevillano and the team of researchers and professors with whom they have been conducting their research have confirmed the presence of graphene oxide nanoparticles in vaccination vials. In program nº63, the team showed some photos of the analyses carried out, specifically results obtained by optical and transmission electron microscopy observation, reserving the results of other techniques used for future programs. They also announced that the report based on all the techniques performed, which allowed determining the presence of graphene oxide, will be made official by the researchers who performed the analyses very soon. Orwell City translated the message from La Quinta Columna and subtitled the video. via Francis Leader

Nanosystems: Molecular Machinery, Manufacturing, and Computation - K. Eric Drexler

Graphene-based sensors used for human health monitoring Since the desire for real-time human health monitoring as well as seamless human-machine interaction is increasing rapidly, plenty of research efforts have been made to investigate wearable sensors and implantable devices in recent years. As a novel 2D material, graphene has aroused a boom in the field of sensor research around the world due to its advantages in mechanical, thermal, and electrical properties. Numerous graphene-based sensors used for human health monitoring have been reported, including wearable sensors, as well as implantable devices, which can realize the real-time measurement of body temperature, heart rate, pulse oxygenation, respiration rate, blood pressure, blood glucose, electrocardiogram signal, electromyogram signal, and electroencephalograph signal, etc. Herein, as a review of the latest graphene-based sensors for health monitoring, their novel structures, sensing mechanisms, technological innovations, components for sensor systems and potential challenges will be discussed and outlined. Frontiers

from this to this

Graphene’s unique properties have engendered high expectations in a host of areas, including for advanced composites and new types of electronic devices. While graphene can come in many forms, its purest form is that of a one-atom-thick layer of graphite. This structure has provided the highest thermal conductivity ever recorded—10 times higher than copper. It also has one of the highest intrinsic electron mobilities of any material (the speed at which electrons can travel through a material), which is approximately 100 times greater than silicon—a tantalizing property for electronic applications. IEEE.org Energy harvested from the device owner You could be the source of power for your next device, if research into TENGs comes to fruition. A TENG - or triboelectric nanogenerator - is a power harvesting technology which captures the electric current generated through contact of two materials. A research team at Surrey's Advanced Technology Institute and the University of Surrey have given an insight into how this technology might be put into place to power things like wearable devices. While we're some way from seeing it in action, the research should give designers the tools they need to effectively understand and optimise future TENG implementation. Future Batteries

The study was conducted by scientists at Graphene Flagship partners the Catalan Institute of Nanoscience and Nanotechnology (ICN2), the Microelectronics Institute of Barcelona (CSIC), CIBER-BBN and ICREA, Spain, Ludwig-Maximilians University, Germany, and the University of Manchester, UK, in collaboration with Graphene Flagship partner Multi Channel Systems GmbH, Germany. The consortium showed that graphene-based sensors grant access to an elusive low-frequency region of brain activity. Current methods to detect brain waves use metallic electrodes, which are ineffective at measuring very low-frequency activity – known as the ‘infra-slow’ region. Thanks to graphene’s sensitivity, scientists can now easily gather information from this region and paint a better picture of animals’ brain activity. This could form the basis for new types of neurotherapeutic medical technology. Using a technology developed by ICN2 and the Microelectronics Institute of Barcelona, in the framework of the Graphene Flagship and the BrainCom European projects, Graphene Flagship scientists built an array of transistors that record and transmit activity information when implanted into the brain. The sensor has small channels on the surface: when they make contact with brain tissue, the electrical signals within the brain cause small changes in conductivity. These changes produce a signal and are recorded to create a brain activity ‘fingerprint.’ “With our array of devices, based on CVD graphene, we can record signals from the infra-slow region with very high accuracy,” Jose Garrido, from Graphene Flagship partner ICN2, Spain, explains. “In the brain, there is a correlation between lower and higher frequencies of brain activity, so the lower frequencies tend to dictate what the higher frequencies look like. We demonstrated that, by measuring the infra-slow activity, with frequencies below a tenth of a hertz, we can decode the ‘brain states’ of an animal.” Garrido believes this technology could lead to new treatments for brain disorders like epilepsy, as certain characteristic signal patterns could reveal ‘brain states’ likely to lead to seizures. To test the device, they implanted it into the brain of a freely behaving rat, monitoring it continuously. The signals were transmitted wirelessly using a miniaturized electronic headstage developed by the industrial partner Multichannel Systems. The scientists found that the signal characteristics measured during different types of brain activity, such as during periods of high activity or during sleep – the so-called ‘brain states’ – correlated very well to the infra-slow signals decoded by the graphene-based implant. Furthermore, Kostas Kostarelos and colleagues at Graphene Flagship partner the University of Manchester, UK, tested the biocompatibility of the devices. They found no inflammation, other than that expected to occur from the device’s implantation, over the entire 12-week duration of their tests, and the device did not degrade over this period. “It is very remarkable to see that we can properly identify and correlate the animals’ brain states with the measured infra-slow activity,” Garrido says. Now, the next step will be to explore commercial applications. “We are already collaborating with some companies interested in this technology, and we aim to translate it into a product – and, beyond that, take it into clinics and hospitals,” he concludes. Serge Picaud, Deputy Leader of the Graphene Flagship’s Biomedical Technologies Work Package, comments: “Novel technologies are always a vector for new discoveries. In this case, graphene sensors have granted us access to the infra-slow brain waves. Recording them in animal models and patients will demonstrate whether we can actually rely on these new measurements for precise diagnostics and treatment options in patients with serious brain diseases like epilepsy.” Andrea C. Ferrari, Science and Technology Officer of the Graphene Flagship and Chair of its Management panel, adds: “The Graphene Flagship recognised the potential of graphene and layered materials for biological applications early on. This remarkable work brings us closer to applications in this area, with a novel tool enabled by the unique properties of graphene.” source thanks to Thirteenth Monkey for the link Thirteenth Monkeys research continues:

13th Monkey is on a ROLL!

Graphene Flagship spin-off INBRAIN raises investment of over €14M INBRAIN Neuroelectronics is bringing a complete technological transformation to the treatment of neurological diseases. Its brain implantable intelligent systems are based on graphene electrodes, which allow miniaturisation to nanoscale fabrication, with the potential to reach single-neuron resolution. The extraordinary properties of graphene ? which is light, biocompatible, flexible and extremely conductive ? are harnessed in much smaller devices that are safer to implant and can be programmed, upgraded and recharged wirelessly. Driven by artificial intelligence, the implant can learn from the brain of each specific patient and trigger adaptive responses to deliver personalised neurological therapy. In addition, the use of big data management will permit remote monitoring of the device and data processing. From Here

INBRAIN Neuroelectronics S.L. is a medical device company dedicated to the development and commercialization of graphene-based neural interfaces and intelligent neuromodulation systems. “Bioelectronic devices have the capability to directly communicate with the nervous system. Recording nerve signals and combining them with other accessible physiological datasets will lead to a better understanding of disease conditions and enable personalized treatment regimens,” said Robert Spoelgen, Head of Bioelectronics, Merck Innovation Center. “We are convinced that bioelectronic devices will play a significant role in the future therapeutic landscape.” InBrain press release

SOMA type stress relief? Engineered small graphene oxide (s-GO) sheets were previously shown to reversibly down-regulate glutamatergic synapses in the hippocampus of juvenile rats, disclosing an unexpected translational potential of these nanomaterials to target selective synapses in vivo. Synapses are anatomical specializations acting in the Central Nervous System (CNS) as functional interfaces among neurons. Dynamic changes in synaptic function, named synaptic plasticity, are crucial to learning and memory. More recently, pathological mechanisms involving dysfunctional synaptic plasticity were implicated in several brain diseases, from dementia to anxiety disorders. Hyper-excitability of glutamatergic neurons in the lateral nucleus of the amygdala complex (LA) is substantially involved in the storage of aversive memory induced by stressful events enabling post-traumatic stress disorder (PTSD). Here we translated in PTSD animal model the ability of s-GO, when stereotaxically administered to hamper LA glutamatergic transmission and to prevent the behavioral response featured in long-term aversive memory. We propose that s-GO, by interference with glutamatergic plasticity, impair LA-dependent memory retrieval related to PTSD. Graphene oxide prevents lateral amygdala dysfunctional synaptic plasticity and reverts long lasting anxiety behavior in rats see also - Wake Up Dopey

very useful for supersoldiers?

“Two days after injecting graphene oxide into a specific region of the mouse’s brain, it behaved like other mice that had never experienced the smell of a cat in their home environment. In other words, graphene oxide inhibited the mouse’s anxiety-related behaviour,” Ballerini explains. She says that two days is roughly the time for memories to form and be consolidated in the mouse’s brain, which corresponds to the time for the symptoms of anxiety to subside. “Graphene oxide interacts with the part of the brain responsible for the formation of fear-related memories, which cause anxiety. It doesn’t work like a drug, by inhibiting the function of the receptors – instead, it temporarily halts the entire mechanism long enough to disrupt the brain’s fear-related pathology, without damaging them,” continues Ballerini. Graphene oxide interrupts anxiety-related neuron signals without affecting the neurons, or the surrounding cells. In simple terms, it only ‘turns down’ the communications between specific neurons. In a disease where these communications are over-expressed, like PTSD and anxiety, targeting the synapses with graphene oxide is enough to halt the development of this pathological behaviour. This is a type of precision medicine." Graphene flagship EU

a telecomms LINK between them all from wireless and Satellite

New graphene optoelectronic mixers boost high speed Telecommunications "The photomixing technique developed in this work is a high impact technology for broad range of applications, such as generation of millimetre waves for future wireless systems and radars, or for ultra-stable frequency generation in all radio systems. In this high impact technology, graphene plays an important role. Thanks to its ultrafast nature, it enables all range of high frequencies and, thanks to its high electrooptical efficiency, graphene generates high frequency electromagnetic waves with unprecedented conversion efficiency that, with further developments, could state new records in performance.” Andrea C. Ferrari, Science and Technology Officer of the Graphene Flagship and Chair of its Management Panel, adds: “We are at the verge of the integration of graphene-based optolectronics into commercial devices. This work, spearheaded by the leading EU Graphene Flagship partner company Thales, shows the industry push for the technology. Our ambition is to see future 5G and 6G devices integrating graphene and layered materials technologies, enabling higher efficiency, speed, and lower power consumption.”" new-graphene-optoelectronic-mixers-boost-high-speed-telecommunications

Suzanne's dream of being a robot!

Suzanne Gildert is currently a founder and CTO of Sanctuary AI. Prior to founding Sanctuary, Suzanne founded Kindred, an artificial intelligence and robotics company. She hand built over 30 robots to demonstrate Kindred’s core technology concept of human robot tele-operation for reinforcement learning. She grew the company to over 50 employees and opened offices in Vancouver, Toronto, and San Mateo. She helped raise over $50M in venture funding for Kindred from top tier investors including Eclipse, Google Ventures, First Round Capital and Data Collective. Suzanne also worked for D-Wave, a Canadian company pioneering quantum computing technology. In 2011, Suzanne joined D-Wave’s machine learning group. In this role she invented and coded most of the use cases D-Wave produced in the period 2011-2013, including MAXCAT, the world’s first quantum computer game, and the world’s first control of a robot by a quantum computer. She also worked on the world’s first supervised binary classifier run on a quantum computer. Her work has been published in several scientific peer reviewed journals, including Nature magazine, and she holds five patents. She led the quantum computing training programs for Lockheed Martin, Google and NASA.

She designed, coded and ran the company’s Developer Portal and the company website. Prior to joining D-Wave, Suzanne worked at the University of Birmingham, UK, where she earned a PhD in Physics and Electronics and subsequently undertook a postdoctoral role. The role focused on cutting edge research with superconducting devices at ultra-low temperatures, giving her a wealth of experience in the design, fabrication and debugging of complex hardware systems. She has worked with hardware at all scales, from microscopic devices up to large, heavy-duty industrial machinery. Suzanne is also a published digital artist and poet, has worked as a graphic designer, and pioneered a technique for creating art using a quantum computer. She loves painting using acrylic on canvas, mixed media, digital painting, tapestry, and she also creates electronic music (synthesizer / keyboard / piano) inspired by retro video games and the synthwave genre. BIO Why would someone who makes robots be an expert in Quantum Computing?

The mind of a robot?

Ray Kurtzweil 2010 reviews his predictions - He's now in charge of R&D at Google

Nanofactory Our nanofactory will be constructed from diamondoid components of the same sort that it can itself manufacture. While molecular manufacturing systems made from DNA, other biopolymers, or even biological organisms are possible, such systems would be unable to build products that approach the remarkable strength, stiffness, temperature range, lightness, electrical, optical and other properties that can achieved with diamondoid materials. and The killer app for digital fabrication is personal fabrication - things you can't buy at Walmart. What if, instead of sending energy, computation, etc. around the world, we sent the means to create it? As regular objects become computerized and interconnected at a smaller and smaller scale, we're approaching the nano-scale of biological systems. We're on the cusp of a fabrication revolution. - Neil Gershenfeld, Director of the Center for Bits and Atoms at MIT, in his SC07 keynote address on 13 November 2007. Molecular assembler

Molecular nanotechnology is the physical underpinning for the singularity

Progress on molecular data storage system Date: February 4, 2020 A team of Brown University researchers has made substantial progress in an effort to create a new type of molecular data storage system. In a study published in Nature Communications, the team stored a variety of image files -- a Picasso drawing, an image of the Egyptian god Anubis and others -- in arrays of mixtures containing custom-synthesized small molecules. In all, the researchers stored more than 200 kilobytes of data, which they say is the most stored to date using small molecules. That's not a lot of data compared to traditional means of storage, but it is significant progress in terms of small molecule storage, the researchers say. "I think this is a substantial step forward," said Jacob Rosenstein, an assistant professor in Brown's School of Engineering and an author of the study. "The large numbers of unique small molecules, the amount of data we can store, and the reliability of the data readout shows real promise for scaling this up even further." As the data universe continues to expand, much work is being done to find new and more compact means of storage. By encoding data in molecules, it may be possible to store the equivalent of terabytes of data in just a few millimeters of space. Most research on molecular storage has focused on long-chain polymers like DNA, which are well known carriers of biological data. But there are potential advantages to using small molecules as opposed to long polymers. Small molecules are potentially easier and cheaper to produce than synthetic DNA, and in theory have an even higher storage capacity.

The Brown research team, supported by a U.S. Defense Advanced Research Projects Agency (DARPA) grant led by chemistry professor Brenda Rubenstein, has been working to find ways of making small-molecule data storage feasible and scalable. To store data, the team uses small metal plates arrayed with 1,500 tiny spots less than a millimeter in diameter. Each spot contains a mixture of molecules. The presence or absence of different molecules in each mixture indicate the digital data. The number of bits in each mixture can be as large as the library of distinct molecules available for mixing. The data can then be read out using a mass spectrometer, which can identify the molecules present in each well. In a paper published last year, the Brown team showed that they could store image files in the kilobyte range using some common metabolites, the molecules that organisms use to regulate metabolism. For this new work, the researchers were able to vastly expand the size of their library -- and thereby the sizes of the files they could encode -- by synthesizing their own molecules. The team made their molecules using Ugi reactions -- a technique often used in the pharmaceutical industry to quickly produce large numbers of different compounds. Ugi reactions combine four broad classes of reagents (an amine, an aldehyde or a ketone, a carboxylic acid, and an isocyanide) into one new molecule. By using different reagents from each class, the researchers could quickly produce a wide array of distinct molecules. For this work, the team used five different amines, five aldehydes, 12 carboxylic acids, and five isocyanides in different combinations to create 1,500 distinct compounds. "The advantage here is the potential scalability of the library," Rubenstein said. "We use just 27 different components to make a 1,500-molecule library in one day. That means we don't have to go out and find 1,500 unique molecules." From there, the team used sub-libraries of compounds to encode their images. A 32-compound library was used to store a binary image of the Egyptian god Anubis. A 575-compound library was used to encode a 0.88-megapixel Picasso drawing of a violin. The large number of molecules available for the chemical libraries also enabled the researchers to explore alternate encoding schemes that made the readout of data more robust. While mass spectrometry is highly precise, it's not perfect. So as with any system used to store or transmit data, this system will need some form of error correction. "The way we design the libraries and read out the data includes extra information that lets us correct some errors," said Brown graduate student Chris Arcadia, first author of the paper. "That helped us streamline the experimental workflow and still get accuracy rates as high as 99 percent." There's still more work to be done to bring this idea up to a useful scale, the researchers say. But the ability to create large chemical libraries and use them for encoding ever larger files suggests the approach can indeed be scaled up. "We're no longer limited by the size of our chemical library, which is really important," Rosenstein said. "That's the biggest step forward here. When we started this project a few years ago, we had some debates about whether something of this scale was even experimentally feasible. So it's really encouraging that we've been able to do this." Other co-authors on the paper were Eamonn Kennedy, Joseph Geiser, Amanda Dombroski, Kady Oakley, Shui-Ling Chen, Leonard Sprague, Mustafa Ozmen, Jason Sello, Peter M. Weber, Sherief Reda, Christopher Rose and Eunsuk Kim. The work was funded by DARPA (W911NF-18-2-0031) and the National Science Foundation (1941344). Science Daily

1960 - There's Plenty of Room at the Bottom An Invitation to Enter a New Field of Physics by Richard P. Feynman

From the Mitre Corporation MATTER AS SOFTWARE James C. Ellenbogen, Ph.D.The MITRE Corporation ABSTRACT In the next century, as the components of computers continue to shrink smaller and smaller,down to the molecular scale, their physical representation will become more and more like that ofpresent-day computer data. It is explained in some detail how this ongoing process ofminiaturization is likely to lead to a technology in which matter will acquire desirable physical andeconomic properties much like those of software. It will be possible to "read" and to "write"functioning computer components and logic structures at will; they will be manufactured locally,on demand, in a manner similar to the way we now "download" software onto disk drives. In addition, microscopic and submicroscopic mutable computer logic structures will be built intomotile microscopic units of matter, putting the macroscopic properties, form, and function ofmatter itself under program control. Thus, in the next century, the technology developed forbuilding dramatically smaller computational engines will evolve to have even broadertechnological and economic impacts than have been felt during the last half century of the digitalcomputer revolution. Mitre.Org

Mitre=MIT - SAGE radar system The MITRE Corporation was chartered in 1958 as a private, not-for-profit company to provide engineering and technical guidance for the federal government. Since then, MITRE has operated at the intersection of advanced technology and vital national concerns. We've grown to serve a variety of government agencies at the highest levels through the operation of federally funded research and development centers (FFRDCs). The company's initial focus was on the continental air defense project called the Semi-Automated Ground Environment (SAGE). SAGE relied on the first digital computers to link radar stations, weapons systems, and military decision makers in near real time. SAGE became operational in 1963. It spawned numerous innovations in computing, software, information displays, communications, program management, and systems engineering. To name a few: the National Airspace System, Airborne Warning and Communications Systems (AWACS), Joint Tactical Information Distribution System (JTIDS), and Joint Surveillance Target Attack Radar System (Joint STARS). relied on the first digital computers to link radar stations, weapons systems, and military decision makers in near real time. MITRE's roots began in the computer laboratories of the Massachusetts Institute of Technology (MIT) during World War II. Throughout the 1940s and early 1950s, MIT's scientists developed the first large-scale digital computer, dubbed Whirlwind I. A group of engineers working at MIT Lincoln Laboratory's Division 6 continued to expand its capabilities. Mitre Corp

Note the acronym - "SAGE"

Japans Moonshot Transhumanist agenda Moonshot report 2021

2.3 Concept To participate in society, regardless of age, culture, physical ability, time or distance it is important for people to enhance their autonomous and interactive activities, and to be able to supplement and complement balanced abilities, and to adapt to changes in the social environment. To realize social participation, the constraints to be considered are “body ability”, “brain ability”, “space and time”, and development of “capability supplementation and replenishment” to control the body and actions in a balanced manner in response to changes in age and social environment. For example, a person who cannot move freely such as an elderly person can overcome this restriction if the physical inability is supplemented or replaced. Furthermore, if a person can augment their physical abilities, things that could not be done before can become achievable. In addition, if a person can use an avatar instead of their body to perform movements, they can share the senses and actions with the avatar and can remotely perform physical work or share experiences.This will make travel cost obsolete: one can work for only 30 minutes every day on the other side of the earth.This will bring about a completely different way of working, and it can be said that avatars will enable the circulation of world-class capabilities. If a person does not have enough experience or knowledge about a perceptional or motion task, capacity augmentation, such as stabilization and acceleration of athletic ability can be built into an avatar.In extreme cases, development of reprogramming of the central nervous system will complementthe memory and experiences, opening up new possibilities. Such capability augmentation would let any person from any background participate in society with greatly reduced obstacles. In WG1, the goal is set to eliminate the constraints of “body ability”,” brain ability”, and “space and time”

Internet of bio nano things

Internet of bio nano things

Flashback - questions asked back in 2004 note: This is before the concepts of 5g, The internet of things / bodies / minds The following is an almagamation of 2 commentarys from my old website - Down with Murder inc It was Johnny Rotten who shouted so wildly 'the futures dream is a shopping spree' and it seems to be the case In July 2004 the then Home secretary David Blunkett introduced War criminal Blair to the UK police conference... he used the phrase 'prison without borders'. and went on to introduce new plans to tag 5000 criminals under a GPS securitys watchful eye. The news media belts out the false premise that a criminal watched is a criminal stopped... think about it... there are more cameras per square yard in this country than in any other...yet the powers that be tell us that crime is still rising. wouldn't this suggest to any fool, that the cameras just ain't working! that indeed people just get used to them and go for it big style...anyway I, for one, have never understood how a camera stops anyone doing anything... ...and there-in lies the reason why this is all being done... The element of fear driven by crime is being used within this technology in order to bribe the population to take part in a social experiment... ...and still the proposals are made, only in this ultra-modern present instead of visible cameras looking over us taking a quiet piss in an alleyway, the cameras are to be hidden in the sky...we are to be chipped, [for our own safety, of course]. to see what the near future holds for us is to turn to the DNA database. Something which i fear is the extension of the demographic tabulating Hollerith machine, which was used to very sinister ends by the Nazis in WWII...counting, labelling people miscreants thus enabling them to experiment on them & kill them... [this should be a lesson to us all- ALWAYS LIE ON QUESTIONAIRES- polls etc] We are constantly reassured that this biotechnology is to be used as a means to find the cure for cancer, AIDS, Alzheimers etc... but where is this cure ? it must be 20-30 years and the promises are STILL coming! Natural GPS. Bats + Genetic engineering = Covid19 = Mrna gene therapy = Imagine a vaccinated public of hive minded Satellite tracked, real time monitoring via their DNA " Being able to chart their position through time with this natural GPS system is one of bats’ greatest survival tools, helping them locate food and evade predators. “The bat must plan both locally in time, and into the future, to be successful in its hunting behaviors,” says Melville Wohlgemuth, a researcher at the University of Arizona’s Batlab. “These are brain processes that are relevant to our lives, as well.” Examining species other than our own has long been a hallmark of neuroscience, and studying the hippocampus of bats could give scientists more insight into how certain diseases affect our own brains. For example, learning more about bats could change how we view Alzheimer’s disease—a brain disorder that slowly destroys cognitive functions and memory. Alzheimer’s patients have trouble intuitively navigating new routes or new locations, even when they’ve encountered them a few times. MIT Technology review what have they been up to? They have been designing diseases that can be patented and propogated in order to keep us in line... the same behavioristic model that is used with Cameras and tracking is to be introduced very soon via Micro-electronic machines [MEMS], into cells & viral bacteria There are reports of Magnetic resonance imaging being experimented with and used within Huge advertising hoardings... indeed this technology- a walk through scanner is being utilised to check for weapons outside clubs in London This is Orwells two way mirror to your soul... Future use of F-MRI [a magnetic resonance imager that reads brain activity in real time] will be an open x-ray to you brains activity... such as the current dreams of neuro marketing...which is cutely referred to as 'pressing the buy button of the brain... if this technology can be used to press a 'buy button'... what other buttons can be pressed? the fear button? the docility button? the death button? vast waves of this energy will flow from advertising screens in malls, and along highways could well be be used as a immune system debilitator, which will allow the influence of mood controlling via induced feelings of sickness/well-being... feelings in which even an incremental amount give rise to a feeling of being under the weather, or 'not myself today'... and in the tradition of Delgado & Skinner, if one makes people feel slighly ill during certain activity, ooh say, like crossing a geo-fencing boundary, they will be far less likely to continue... it's the usual suspects It's all connected Border control - HAARP - Radar Satellite Global positioning systems, Privatized intelligence companies Will people walking through Shopping malls & driving along freeways be bathed in FMRI, constantly urging us to feel a certain way? constantly scanning us for 'abnormalities' & labelling as 'terrorists'? Bruce Wayne's mass surveillance system in The Dark Knight. Privacy themes in Dark Knight and Dark Knight Rises In The Dark Knight, Bruce Wayne/Batman (Christian Bale) has arms inventor extraordinaire Lucius Fox (Morgan Freeman) build a mass surveillance system to spy on Gotham City’s citizens using video and mobile phone technology. Despite Fox threatening to quit over the system because it violated innocent citizens’ privacy, Wayne argued that it was necessary to catch Joker. In the end, Wayne destroyed the system. The argument that widespread surveillance–and thus infringing on people’s civil liberties–is necessary to stop terrorism is very common. That argument is the basis for the more than 1.3 million law enforcement requests each year for US residents’ cell phone records. It’s why private companies like Verizon, AT&T, and Google have to turn over your personal information when law enforcement asks for it. It’s why the National Security Agency (NSA) is currently building a $2 billion surveillance center to intercept the communications of every American. - Sarah Downey - from 2012 Govt. of Canada The internet of BIO NANO THINGS The future [see hidden present] systems of control are preparing the human race for a dependance on disease...a normality virus, with which they can hold the big stick of disease on any human[s] that need 'democratizing' in the war on terror...it is economic, phrma-based warfare... Disease patenting? Cancer patenting? Disease MANAGEMENT ? disease used as the punishment for subversive/militant thought? will the herd evolve via this behaviorism into not wanting to rebel because it makes them feel ill? Will Orwells 2 - way TV be an fMRI scanner? Could a system of Optical satellite tracking, 3d radar, RFID, Bluetooth & Brain-interface technology come to resemble a form bio-tech remote viewing? Will this spy network be able to hack into your brain via a secret backdoor and sense what you sense? Is it just my imagination? will "the central control" (added 2021) be located via the DNA database - used as you would a telephone directory The upgradable nano-scale RFID / MMEA chip will be your passport to goods and services example: normal surveillance: find target = spy & view target new concept: find target = locate window, spy and view through target Any human will be the 'window' The system admin can hack into anyones braincode - via electrical signal to and from the brain. The brains signal is then decoded and remotely watched as a hologram. The death of privacy - potentially using anyone as a spy. With the possibility of 'secret backdoor technology' being written into this Brain Machine Interface, Memory and perception could also be altered, with the possibility that ultra secrets could be stored in an unsuspecting citizen.